- Najarian: Options Get Bullish on Cisco
- Four Hardware Stocks Upgraded by Goldman
- Options Smell 'Blood' on Infosys
- Art Cashin: Traders Weigh Obama Policy Changes
- S&P's Stovall: Pullback to 810 is Likely
- What Options Say About Transports Now
- Art Cashin: Stimulus Package Was a 'Hoax'
- Healthcare Gains and Other Signs of the Bear
- What's The Biggest Options Trade Today?
- Santelli Debate: Are Banks On the Right Track?
|
CNBC'S MOST SHARED
- Investing in Tech Now
- What You'll See On My NASCAR Documentary Tonight
- Warren Buffett Tells CNBC Consumer Sales Remain "Very, Very Soft"
- Warren Buffett's Complete Sun Valley CNBC Interview - Transcript and Video
- Software Giants Rush to Cash In on Carbon Counting
- Apartment Vacancy Rate Hits 22-Year High
- Preparing for Retirement
- Microsoft Plays a Game of Bing Pong
- 15 Stocks to Consider
- Maximum Bob Goes Full Throttle For GM
- Najarian: Options Get Bullish on Cisco
- Sun Valley on Social Media
- Four Hardware Stocks Upgraded by Goldman
- Eric Schmidt + Larry Page on Revolutionizing Computing
- Warren Buffett's Complete Sun Valley CNBC Interview - Transcript and Video
- Warren Buffett Tells CNBC Consumer Sales Remain "Very, Very Soft"
- July 10th in Market History
- Consumers' Mood Sours in Early July
- Trade Deficit Lowest in 10 Years; Import Prices Jump
- Obama: Full Economic Recovery 'A Ways Off'
- Cisco Cutting up to 2,000 Jobs, Analyst Says
- Geithner To Call for Policing of Derivatives
- AIG Prepares to Pay More Bonuses to Executives
- UBS Can't Comply with US Request: Internal Memo
- Treasury Sold Warrants Below Market Value: Panel
- Chevron Warns Earnings Hit by Weak Refining Margins
RSS FEED
Text Size 
Two strategists, Stephen Wood at Russell Investments and John Manley at Citi Smith Barney, shared their market rebound strategies with CNBC.
“Health care is a good place to be,” said Manley. “Biotech [stocks] are cheap, and some of the big pharmaceutical companies have done nothing good for eight years. [Although] there’s a general fear that you don’t want to own any stocks before an election, when I see a consensus that rock-hard, I think there may be an opposite side to it.”
Wood, however, disagreed with Manley.
“I’m not as convinced with the election trade as a lot of people are,” he said. “I’m waiting for a lot of specifics from both candidates, but making big bets based on an election year may not be a good idea.”
Disclosures:
Disclosure information for Stephen Wood and John Manley were not immediately available.
_________________________________
Top biotech names:
Biogen Idec [BIIB
Loading...
()
]
Genentech [DNA
Loading...
()
]
Amgen [AMGN
Loading...
()
]
Genzyme [GENZ
Loading...
()
]
Celgene [CELG
Loading...
()
]
_________________________________
Data is a real-time snapshot *Data is delayed at least 15 minutes